ConductScience.org, home

Paper609192

Kinetics of procainamide and N-acetylprocainamide in renal failure.

Gibson TP and 4 others. Kidney Int, 1977. Cited by 82 papers, by iCite.

Cite this record

ConductScience Library. Kinetics of procainamide and N-acetylprocainamide in renal failure. Papers, record 609192. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/609192

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Kinetics of procainamide and N-acetylprocainamide in renal failure.
PubMed
Journal
Kidney Int
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
82
iCite
Relative citation ratio, by iCite
4.25
iCite
Revised in PubMed
2019-07-25
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gibson TPT P
2Atkinson AJ JrA J
3Matusik EE
4Nelson LDL D
5Briggs WAW A

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Kidney Failure, ChronicMajor topic
ProcainamideMajor topic
Adult
Female
Half-Life
Humans
Kinetics
Male
Metabolic Clearance Rate
Middle Aged
Nephrectomy
Time Factors

Source PubMed

Download CSV of topics

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.

PMIDTitleJournalYearIn PapersSource
30845766Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and N-Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats.Pharmaceutics2019https://conductscience.org/library/papers/30845766PubMed
25855244A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.Semin Dial2015https://conductscience.org/library/papers/25855244PubMed
18680441The effect of chronic renal failure on drug metabolism and transport.Expert Opin Drug Metab Toxicol2008https://conductscience.org/library/papers/18680441PubMed
9839088Clinical pharmacokinetics of diacerein.Clin Pharmacokinet1998https://conductscience.org/library/papers/9839088PubMed
7957446Influence of renal function on the pharmacokinetics of diacerein after a single oral dose.Eur J Drug Metab Pharmacokinet1994https://conductscience.org/library/papers/7957446PubMed
7037261Drug metabolites in renal failure: pharmacokinetic and clinical implications.Clin Pharmacokinet1981https://conductscience.org/library/papers/7037261PubMed
6988197The pharmacological role of the kidney.Drugs1980https://conductscience.org/library/papers/6988197PubMed
6362952Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.Clin Pharmacokinet1984https://conductscience.org/library/papers/6362952PubMed
6194997Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.Eur J Clin Pharmacol1983https://conductscience.org/library/papers/6194997PubMed
6178545Clinical pharmacokinetics of N-acetylprocainamide.Clin Pharmacokinet1982https://conductscience.org/library/papers/6178545PubMed
3729324Pharmacokinetics of carumonam in patients with renal insufficiency.Antimicrob Agents Chemother1986https://conductscience.org/library/papers/3729324PubMed
3709612Pharmacokinetics of tenoxicam in patients with impaired renal function.Eur J Clin Pharmacol1986https://conductscience.org/library/papers/3709612PubMed
3707111Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin.Antimicrob Agents Chemother1986https://conductscience.org/library/papers/3707111PubMed
3060292Guide to drug dosage in renal failure.Clin Pharmacokinet1988https://conductscience.org/library/papers/3060292PubMed
2737232High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance.Eur J Clin Pharmacol1989https://conductscience.org/library/papers/2737232PubMed
2613484Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.Int Urol Nephrol1989https://conductscience.org/library/papers/2613484PubMed
2610506Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2610506PubMed
2029806Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.Clin Pharmacokinet1991https://conductscience.org/library/papers/2029806PubMed
458558Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.J Pharmacokinet Biopharm1979https://conductscience.org/library/papers/458558PubMed
22417Drug kinetics and artificial kidneys.Clin Pharmacokinet1977https://conductscience.org/library/papers/22417PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/609192

GET https://conductscience.org/api/papers/v1/609192/authors